Patrick Plesiat

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1140092/publications.pdf

Version: 2024-02-01

130 papers	7,883 citations	57758 44 h-index	54911 84 g-index
133 all docs	133 docs citations	133 times ranked	8326 citing authors

#	Article	IF	Citations
1	The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria. Clinical Microbiology Reviews, 2015, 28, 337-418.	13.6	1,097
2	Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clinical Microbiology and Infection, 2007, 13, 560-578.	6.0	455
3	Resistance to polymyxins in Gram-negative organisms. International Journal of Antimicrobial Agents, 2017, 49, 526-535.	2.5	301
4	In Vivo Emergence of Multidrug-Resistant Mutants of Pseudomonas aeruginosa Overexpressing the Active Efflux System MexA-MexB-OprM. Antimicrobial Agents and Chemotherapy, 1999, 43, 287-291.	3.2	248
5	The Pseudomonas aeruginosa opportunistic pathogen and human infections. Environmental Microbiology, 2011, 13, 1655-1665.	3.8	239
6	Emergence of Imipenem-Resistant Gram-Negative Bacilli in Intestinal Flora of Intensive Care Patients. Antimicrobial Agents and Chemotherapy, 2013, 57, 1488-1495.	3.2	227
7	Clinical Strains of Pseudomonas aeruginosa Overproducing MexAB-OprM and MexXY Efflux Pumps Simultaneously. Antimicrobial Agents and Chemotherapy, 2004, 48, 1797-1802.	3.2	226
8	Mutations in Î²-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins. Antimicrobial Agents and Chemotherapy, 2015, 59, 6248-6255.	3.2	187
9	Outer membranes of Gram-negative bacteria are permeable to steroid probes. Molecular Microbiology, 1992, 6, 1323-1333.	2.5	181
10	A Two-Component Regulatory System Interconnects Resistance to Polymyxins, Aminoglycosides, Fluoroquinolones, and Î²-Lactams inPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2011, 55, 1211-1221.	3.2	176
11	MexXY-OprM Efflux Pump Is Necessary for Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2003, 47, 1371-1375.	3.2	153
12	Induction of the MexXY Efflux Pump in Pseudomonas aeruginosa Is Dependent on Drug-Ribosome Interaction. Journal of Bacteriology, 2005, 187, 5341-5346.	2.2	133
13	Involvement of the MexXY-OprM Efflux System in Emergence of Cefepime Resistance in Clinical Strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2006, 50, 1347-1351.	3.2	128
14	Role of the Multidrug Efflux System MexXY in the Emergence of Moderate Resistance to Aminoglycosides among Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2004, 48, 1676-1680.	3.2	126
15	Mutations in PA3574 (nalD) Lead to Increased MexAB-OprM Expression and Multidrug Resistance in Laboratory and Clinical Isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2005, 49, 1782-1786.	3.2	126
16	Heterogeneous Vancomycinâ€Intermediate Susceptibility Phenotype in Bloodstream Methicillinâ€ResistantStaphylococcus aureusIsolates from an International Cohort of Patients with Infective Endocarditis: Prevalence, Genotype, and Clinical Significance. Journal of Infectious Diseases, 2009, 200, 1355-1366.	4.0	120
17	Resistance and Virulence of Pseudomonas aeruginosa Clinical Strains Overproducing the MexCD-OprJ Efflux Pump. Antimicrobial Agents and Chemotherapy, 2008, 52, 2455-2462.	3.2	111
18	Evidence for Induction of Integron-Based Antibiotic Resistance by the SOS Response in a Clinical Setting. PLoS Pathogens, 2012, 8, e1002778.	4.7	109

#	Article	IF	Citations
19	Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy, 2016, 60, 7415-7423.	3.2	99
20	Role of the MexEF-OprN Efflux System in Low-Level Resistance of Pseudomonas aeruginosa to Ciprofloxacin. Antimicrobial Agents and Chemotherapy, 2011, 55, 5676-5684.	3.2	98
21	Validated Risk Score for Predicting 6â€Month Mortality in Infective Endocarditis. Journal of the American Heart Association, 2016, 5, e003016.	3.7	98
22	Cumulative Effects of Several Nonenzymatic Mechanisms on the Resistance of Pseudomonas aeruginosa to Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2007, 51, 1016-1021.	3.2	95
23	Multiple Mutations Lead to MexXY-OprM-Dependent Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2014, 58, 221-228.	3.2	93
24	Pseudomonas aeruginosa May Accumulate Drug Resistance Mechanisms without Losing Its Ability To Cause Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2007, 51, 3531-3536.	3.2	91
25	Efflux Unbalance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2009, 53, 1987-1997.	3.2	91
26	Increased Susceptibility of Pseudomonas aeruginosa to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of oprM and Increased Outer-Membrane Permeability. Clinical Infectious Diseases, 2012, 55, 534-542.	5.8	90
27	Antibiotic Resistance Determinants in a Pseudomonas putida Strain Isolated from a Hospital. PLoS ONE, 2014, 9, e81604.	2.5	86
28	Genetic and Phenotypic Variations of a Resistant Pseudomonas aeruginosa Epidemic Clone. Antimicrobial Agents and Chemotherapy, 2003, 47, 1887-1894.	3.2	85
29	Impact of Early Valve Surgery on Outcome of Staphylococcus aureus Prosthetic Valve Infective Endocarditis: Analysis in the International Collaboration of Endocarditisâ€"Prospective Cohort Study. Clinical Infectious Diseases, 2015, 60, 741-749.	5.8	84
30	Genotypic and Phenotypic Analysis of Type III Secretion System in a Cohort ofPseudomonas aeruginosaBacteremia Isolates: Evidence for a Possible Association between O Serotypes andexoGenes. Journal of Infectious Diseases, 2003, 188, 512-518.	4.0	83
31	Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2013, 68, 1772-1780.	3.0	78
32	Rapid detection and discrimination of chromosome- and MCR-plasmid-mediated resistance to polymyxins by MALDI-TOF MS in Escherichia coli: the MALDIxin test. Journal of Antimicrobial Chemotherapy, 2018, 73, 3359-3367.	3.0	66
33	Unique Biofilm Signature, Drug Susceptibility and Decreased Virulence in Drosophila through the Pseudomonas aeruginosa Two-Component System PprAB. PLoS Pathogens, 2012, 8, e1003052.	4.7	65
34	Mutations in Gene fusA1 as a Novel Mechanism of Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	61
35	Rapid detection of colistin resistance in Acinetobacter baumannii using MALDI-TOF-based lipidomics on intact bacteria. Scientific Reports, 2018, 8, 16910.	3.3	61
36	Uptake of Pyocin S3 Occurs through the Outer Membrane Ferripyoverdine Type II Receptor of Pseudomonas aeruginosa. Journal of Bacteriology, 1999, 181, 3849-3851.	2.2	61

#	Article	IF	Citations
37	Diversity of Â-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study. Journal of Antimicrobial Chemotherapy, 2013, 68, 1763-1771.	3.0	59
38	Pyomelaninâ€producing Pseudomonas aeruginosa selected during chronic infections have a large chromosomal deletion which confers resistance to pyocins. Environmental Microbiology, 2016, 18, 3482-3493.	3.8	57
39	Nationwide Investigation of Extended-Spectrum Î²-Lactamases, Metallo-Î²-Lactamases, and Extended-Spectrum Oxacillinases Produced by Ceftazidime-Resistant Pseudomonas aeruginosa Strains in France. Antimicrobial Agents and Chemotherapy, 2010, 54, 3512-3515.	3.2	56
40	Naturally Occurring Class A ÃŸ-Lactamases from the Burkholderia cepacia Complex. Antimicrobial Agents and Chemotherapy, 2009, 53, 876-882.	3.2	51
41	Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. Journal of Antimicrobial Chemotherapy, 2007, 59, 1021-1024.	3.0	50
42	Alternatives to carbapenems in ESBL-producing Escherichia coli infections. MÃ©decine Et Maladies Infectieuses, 2013, 43, 62-66.	5.0	50
43	A Standard Numbering Scheme for Class C Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	50
44	Detection of an IS21 insertion sequence in the mexR gene of Pseudomonas aeruginosa increasing ÃŽÂ²-lactam resistance. FEMS Microbiology Letters, 2004, 230, 143-146.	1.8	49
45	MexAB-OprM- and MexXY-Overproducing Mutants Are Very Prevalent among Clinical Strains of Pseudomonas aeruginosa with Reduced Susceptibility to Ticarcillin. Antimicrobial Agents and Chemotherapy, 2007, 51, 1582-1583.	3.2	48
46	Microbiological and Epidemiological Features of Clinical Respiratory Isolates of Burkholderia gladioli. Journal of Clinical Microbiology, 2009, 47, 1510-1516.	3.9	48
47	Propagation of TEM- and PSE-Type Î²-Lactamases among Amoxicillin-Resistant Salmonella spp. Isolated in France. Antimicrobial Agents and Chemotherapy, 1999, 43, 2430-2436.	3.2	46
48	Amino Acid Substitutions Account for Most MexS Alterations in Clinical nfxC Mutants of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2016, 60, 2302-2310.	3.2	45
49	Resistance of Animal Strains of Pseudomonas aeruginosa to Carbapenems. Frontiers in Microbiology, 2017, 8, 1847.	3.5	44
50	Relationship between Antibiotic Use and Incidence of MexXY-OprM Overproducers among Clinical Isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2008, 52, 1173-1175.	3.2	42
51	Acquired resistance to macrolides inPseudomonas aeruginosafrom cystic fibrosis patients. European Respiratory Journal, 2017, 49, 1601847.	6.7	42
52	Genotypic Diversity of Coagulase-Negative Staphylococci Causing Endocarditis: a Global Perspective. Journal of Clinical Microbiology, 2008, 46, 1780-1784.	3.9	40
53	Carbapenem resistance in cystic fibrosis strains of Pseudomonas aeruginosa as a result of amino acid substitutions in porin OprD. International Journal of Antimicrobial Agents, 2015, 45, 529-532.	2.5	39
54	Molecular Analysis of the Replication Elements of the Broad-Host-Range RepA/C Replicon. Plasmid, 1996, 36, 26-35.	1.4	38

#	Article	IF	Citations
55	Diabetes mellitus and infective endocarditis: the insulin factor in patient morbidity and mortality. European Heart Journal, 2006, 28, 59-64.	2.2	38
56	First Detection of GES-5 Carbapenemase-ProducingAcinetobacter baumanniiIsolate. Microbial Drug Resistance, 2017, 23, 556-562.	2.0	36
57	Toxic Electrophiles Induce Expression of the Multidrug Efflux Pump MexEF-OprN in Pseudomonas aeruginosa through a Novel Transcriptional Regulator, CmrA. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	35
58	Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	35
59	Elimination of plasmids from Enterobacteriaceae by 4-quinolone derivatives. Journal of Antimicrobial Chemotherapy, 1986, 18, 667-674.	3.0	34
60	Prospective evaluation of an algorithm for the phenotypic screening of carbapenemase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2016, 71, 135-140.	3.0	34
61	Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic. Scientific Reports, 2017, 7, 40208.	3.3	34
62	The Efflux Pump MexXY/OprM Contributes to the Tolerance and Acquired Resistance of Pseudomonas aeruginosa to Colistin. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	32
63	Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2005, 55, 518-522.	3.0	31
64	Genetic analysis of a multiresistant strain of Pseudomonas aeruginosa producing PER-1 Î²-lactamase. Clinical Microbiology and Infection, 2006, 12, 270-278.	6.0	28
65	Phylogenetic Analysis of Viridans Group Streptococci Causing Endocarditis. Journal of Clinical Microbiology, 2008, 46, 3087-3090.	3.9	28
66	Avibactam confers susceptibility to a large proportion of ceftazidime-resistantPseudomonas aeruginosaisolates recovered from cystic fibrosis patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1596-1598.	3.0	27
67	Diversity of Molecular Mechanisms Conferring Carbapenem Resistance toPseudomonas aeruginosaIsolates from Saudi Arabia. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-7.	1.9	27
68	Molecular epidemiology of multidrug-resistant Pseudomonas aeruginosa in a French university hospital. Journal of Hospital Infection, 2010, 76, 316-319.	2.9	26
69	Selection of an Antibiotic-Hypersusceptible Mutant of Pseudomonas aeruginosa : Identification of the GlmR Transcriptional Regulator. Antimicrobial Agents and Chemotherapy, 2004, 48, 843-851.	3.2	25
70	Predominance of healthcare-associated cases among episodes of community-onset bacteraemia due to extended-spectrum Î²-lactamase-producing Enterobacteriaceae. International Journal of Antimicrobial Agents, 2017, 49, 67-73.	2.5	24
71	Cinnamaldehyde Induces Expression of Efflux Pumps and Multidrug Resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	24
72	Cost-effectiveness of urinary dipsticks to screen asymptomatic catheter-associated urinary infections in an intensive care unit. Intensive Care Medicine, 2001, 27, 1842-1847.	8.2	23

#	Article	IF	Citations
73	Unexpected persistence of extended-spectrum Î²-lactamase-producing Enterobacteriaceae in the faecal microbiota of hospitalised patients treated with imipenem. International Journal of Antimicrobial Agents, 2017, 50, 81-87.	2.5	23
74	Constitutive Activation of MexT by Amino Acid Substitutions Results in MexEF-OprN Overproduction in Clinical Isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	23
75	Evaluation of the Immunochromatographic NG-Test Carba 5 for Rapid Identification of Carbapenemase in Nonfermenters. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	23
76	Higher Prevalence of PldA, a Pseudomonas aeruginosa Trans-Kingdom H2-Type VI Secretion System Effector, in Clinical Isolates Responsible for Acute Infections and in Multidrug Resistant Strains. Frontiers in Microbiology, 2018, 9, 2578.	3.5	22
77	A Convenient Method To Screen for Carbapenemase-Producing Pseudomonas aeruginosa. Journal of Clinical Microbiology, 2013, 51, 3846-3848.	3.9	21
78	Human Cysteine Cathepsins Are Not Reliable Markers of Infection by Pseudomonas aeruginosa in Cystic Fibrosis. PLoS ONE, 2011, 6, e25577.	2.5	21
79	Detection of a new extended-spectrum oxacillinase in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2010, 65, 364-365.	3.0	20
80	Increase of efflux-mediated resistance in Pseudomonas aeruginosa during antibiotic treatment in patients suffering from nosocomial pneumonia. International Journal of Antimicrobial Agents, 2016, 47, 77-83.	2.5	20
81	Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137. Journal of Cystic Fibrosis, 2019, 18, 804-807.	0.7	20
82	Ceftazidime-hydrolysing Â-lactamase OXA-145 with impaired hydrolysis of penicillins in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2011, 66, 1745-1750.	3.0	19
83	ISAba1-dependent overexpression of eptA in clinical strains of Acinetobacter baumannii resistant to colistin. Journal of Antimicrobial Chemotherapy, 2019, 74, 2544-2550.	3.0	19
84	Identification of Diverse Integron and Plasmid Structures Carrying a Novel Carbapenemase Among Pseudomonas Species. Frontiers in Microbiology, 2019, 10, 404.	3.5	19
85	Pseudomonas aeruginosa Genome Evolution in Patients and under the Hospital Environment. Pathogens, 2014, 3, 309-340.	2.8	18
86	Production of Norspermidine Contributes to Aminoglycoside Resistance in pmrAB Mutants of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	18
87	Outbreak of metallo-Â-lactamase VIM-2-positive strains of Pseudomonas aeruginosa in the Ivory Coast. Journal of Antimicrobial Chemotherapy, 2013, 68, 2952-2954.	3.0	17
88	Antibiotic susceptibility and mechanisms of Î²-lactam resistance among clinical strains of PseudomonasÂaeruginosa: First report in Algeria. MÃ©decine Et Maladies Infectieuses, 2008, 38, 187-191.	5.0	16
89	IMP-29, a Novel IMP-Type Metallo-Î²-Lactamase in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2012, 56, 2187-2190.	3.2	16
90	Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2012, 67, 771-775.	3.0	16

#	Article	IF	Citations
91	Type III Secretion System and Virulence Markers Highlight Similarities and Differences between Human- and Plant-Associated Pseudomonads Related to Pseudomonas fluorescens and P. putida. Applied and Environmental Microbiology, 2015, 81, 2579-2590.	3.1	16
92	Involvement of the Pseudomonas aeruginosa MexABâ€“OprM efflux pump in the secretion of the metallophore pseudopaline. Molecular Microbiology, 2021, 115, 84-98.	2.5	16
93	Strain-Tailored Double-Disk Synergy Test Detects Extended-Spectrum Oxacillinases in Pseudomonas aeruginosa. Journal of Clinical Microbiology, 2011, 49, 2262-2265.	3.9	15
94	Spread of the blaIMP-13 gene in French Pseudomonas aeruginosa through sequence types ST621, ST308 and ST111. International Journal of Antimicrobial Agents, 2012, 40, 571-573.	2.5	15
95	Antimicrobial Drug Efflux Pumps in Pseudomonas aeruginosa. , 2016, , 359-400.		14
96	Improvement of a disk diffusion method for antibiotic susceptibility testing of anaerobic bacteria. French recommendations revisited for 2020. Anaerobe, 2020, 64, 102213.	2.1	13
97	Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes From a Large, Multinational Cohort. Open Forum Infectious Diseases, 2020, 7, ofaa120.	0.9	12
98	Detection of Colistin Resistance in Pseudomonas aeruginosa Using the MALDIxin Test on the Routine MALDI Biotyper Sirius Mass Spectrometer. Frontiers in Microbiology, 2021, 12, 725383.	3.5	12
99	Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry. PLoS ONE, 2019, 14, e0210201.	2.5	11
100	Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing ofPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2021, 76, 2586-2592.	3.0	11
101	Carbapenem-Susceptible OXA-23-Producing Proteus mirabilis in the French Community. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	10
102	In vitro activities of a new fluoroquinolone derivative highly active against Chlamydia trachomatis. Bioorganic Chemistry, 2019, 83, 180-185.	4.1	10
103	Acquisition of Class C Î²-Lactamase PAC-1 by Sequence Type 644 Strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
104	Sequential emergence of colistin and rifampicin resistance in an OXA-72- producing outbreak strain of Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2019, 53, 669-673.	2.5	9
105	Chryso-lactams:Gold(I) derivatives of ampicillin with specific activity against Gram-positive pathogens. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127098.	2.2	9
106	In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin. Clinical Microbiology and Infection, 2006, 12, 426-432.	6.0	8
107	An unusual community-acquired invasive and multi systemic infection due to ExoU-harboring Pseudomonas aeruginosa strain: Clinical disease and microbiological characteristics. Journal of Microbiology, Immunology and Infection, 2020, 53, 647-651.	3.1	8
108	Infective Endocarditis Related to Unusual Microorganisms: A Prospective Population-Based Study. Open Forum Infectious Diseases, 2020, 7, ofaa127.	0.9	8

#	Article	IF	Citations
109	Molecular and epidemiological investigation of a colistin-resistant OXA-23-/NDM-1-producing Acinetobacter baumannii outbreak in the Southwest Indian Ocean Area. International Journal of Antimicrobial Agents, 2021, 58, 106402.	2.5	8
110	A case of multiple contamination with methylase ArmA-producing pathogens. Journal of Antimicrobial Chemotherapy, 2017, 72, 618-620.	3.0	7
111	The Transcriptional Repressor SmvR Is Important for Decreased Chlorhexidine Susceptibility in Enterobacter cloacae Complex. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	7
112	Development of a Multiple-Locus Variable-Number Tandem-Repeat Typing Scheme for Genetic Fingerprinting of Burkholderia cenocepacia and Application to Nationwide Epidemiological Analysis. Journal of Clinical Microbiology, 2015, 53, 398-409.	3.9	6
113	Reassessment of the cooperativity between efflux system MexAB-OprM and cephalosporinase AmpC in the resistance of Pseudomonas aeruginosa to Î²-lactams. Journal of Antimicrobial Chemotherapy, 2021, 76, 536-539.	3.0	6
114	Serological biomarkers for the diagnosis of Mycobacterium abscessus infections in cystic fibrosis patients. Journal of Cystic Fibrosis, 2022, 21, 353-360.	0.7	6
115	Hospital outbreak of Pseudomonas aeruginosa producing extended-spectrum oxacillinase OXA-19. Journal of Medical Microbiology, 2010, 59, 866-869.	1.8	5
116	Pseudomonas aeruginosa et rÃ©sistance aux antibiotiques. Revue Francophone Des Laboratoires, 2011, 2011, 49-62.	0.0	5
117	A novel IncQ plasmid carrying geneblaCTX-M-3 inPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2019, 74, 823-825.	3.0	5
118	Pseudomonas aeruginosa: Une virulence complexe. Revue Francophone Des Laboratoires, 2011, 2011, 73-81.	0.0	4
119	Difficult-to-detect carbapenem-resistant IMP13-producing P. aeruginosa: experience feedback concerning a cluster of urinary tract infections at a surgical clinic in France. Antimicrobial Resistance and Infection Control, 2013, 2, 12.	4.1	4
120	Clonal Dissemination of Pseudomonas aeruginosa Isolates Producing Extended-Spectrum Î²-Lactamase SHV-2a. Journal of Clinical Microbiology, 2013, 51, 673-675.	3.9	4
121	A case of leech-associated infection involving an extended-spectrum Î²-lactamase-producing and extensively drug-resistant Aeromonas hydrophila. Clinical Microbiology and Infection, 2019, 25, 394-395.	6.0	4
122	Coordinate overexpression of two <scp>RND</scp> efflux systems, <scp>ParXY</scp> and <scp>TtgABC</scp>, is responsible for multidrug resistance in Pseudomonas putida. Environmental Microbiology, 2020, 22, 5222-5231.	3.8	4
123	Targeted Genome Reduction of Pseudomonas aeruginosa Strain PAO1 Led to the Development of Hypovirulent and Hypersusceptible rDNA Hosts. Frontiers in Bioengineering and Biotechnology, 2021, 9, 640450.	4.1	4
124	Genomic analysis of CTX-M-115 and OXA-23/-72 co-producing Acinetobacter baumannii, and their potential to spread resistance genes by natural transformation. Journal of Antimicrobial Chemotherapy, 2022, 77, 1542-1552.	3.0	4
125	Emergence of plasmid-mediated colistin resistance (mcr-1) among Enterobacteriaceae strains: Laboratory detection of resistance and measures to control its dissemination. MÃ©decine Et Maladies Infectieuses, 2018, 48, 250-255.	5.0	3
126	1,2,3-Triazole-gold(I)-triethylposphine derivatives active against resistant Gram-positive pathogens. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127879.	2.2	3

#	Article	IF	Citations
127	Negative Impact of Citral on Susceptibility of Pseudomonas aeruginosa to Antibiotics. Frontiers in Microbiology, 2021, 12, 709838.	3.5	3
128	IgA Serological Response for the Diagnosis of Mycobacterium abscessus Infections in Patients with Cystic Fibrosis. Microbiology Spectrum, 2022, 10, e0019222.	3.0	3
129	Drug Susceptibility Testing by Dilution Methods. Methods in Molecular Biology, 2014, 1149, 49-58.	0.9	1
130	Ã‰pidÃ©miologie de la rÃ©sistance aux Î²-lactamines chez Pseudomonas aeruginosa. Journal Des Anti-infectieux, 2016, 18, 52-63.	0.1	0